119. The delegation of Japan would like to express our gratitude to the Secretariat for preparing a draft report so we can review the Special Compulsory Licensing System. We welcome this work, hoping that it will encourage all remaining Members to notify their acceptance of the Protocol.
120. This delegation would like to reiterate the importance of access to medicines, which needs to be discussed in a broader context, taking into account not only the Special Compulsory Licensing System, but also various other relevant measures and factors, such as procurement and tariffs. Japan supports the Paragraph 6 System as established under the 2003 Waiver Decision and the 2005 Protocol Amending the TRIPS Agreement. The very objective of the System is to support WTO Members in obtaining greater access to medicines, specifically Members that have either insufficient or no pharmaceutical manufacturing capacity. Compulsory licenses are, whether granted under the System or not, just one of the potential means that can be utilized for this objective under an exceptional circumstance and, therefore, the System should not be considered as the only solution, but rather as just an option we could consider.
121. In addition, this delegation would like to mention that voluntary efforts to streamline access to medicines have been increasing. For example, in September WIPO and IFPMA collaboratively launched a new medicinal patent information database, Pat-INFORMED, to help procurement agencies better understand the global patent status of medicines. We believe such a voluntary and collaborative effort will be one of the possible ways forward to respond to better access to medicines.